AtriCure, Inc.
NASDAQ:ATRCMedical - Instruments & Supplies
+$0.96 today
- Market cap
- $2.82B
- Beta
- 1.26
- P/E (TTM)
- -295.5
- EPS (TTM)
- -$0.10
Volume 0.60M
Average 0.77M
ATRC Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
AtriCure, Inc.NASDAQ: ATRC
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development declines year over year
Q2 FY2026 research & development of $26.4M fell 9.8% year over year, ahead of the -10.6% change in trailing-twelve-month research & development. Sequentially, it rose 8.9% from the prior quarter. Over 3 fiscal years it compounded at +16.3% a year.
Context
- Research & development amounted to 16.9% of revenue in FY2025, down 3.8 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -9.8% holds above the trailing-twelve-month pace of -10.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 90.17M USD
- Year-over-year change
- -6.2%
- 4-year CAGR
- +16.8%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 90.17M | -6.2% |
| FY2024 | 2024-12-31 | 96.18M | +30.1% |
| FY2023 | 2023-12-31 | 73.92M | +28.9% |
| FY2022 | 2022-12-31 | 57.34M | +18.2% |
| FY2021 | 2021-12-31 | 48.51M | — |
Research & Development vs competitors
How ATRC compares with its peers on the latest reported figures
- ATRC's LTM Jun 2026 research & development of $96.27M is the lowest of the 5 companies compared; the peer median is $1.62B.
- Its year-over-year change of -10.6% is the lowest of 5, against a peer median of +9.7%.
- Research & development amounts to 16.9% of revenue for ATRC, versus a peer median of 11.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $2.92B | +4.9% | +2.1% | 7.8% | |
| LTM Jun 2026 | $2.15B | +17.3% | +15.8% | 10.3% | |
| LTM Jun 2026 | $1.09B | +3.3% | +4.5% | 16.7% | |
| LTM Sep 2026 | $202.57M | +14.5% | +6.0% | 13.4% | |
| LTM Jun 2026 | $96.27M | -10.6% | +16.3% | 16.9% | |
| Peer median (excluding ATRC) | $1.62B | +9.7% | +5.3% | 11.8% | |
Competitors are the stored peer set for ATRC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 274.33M | 330.38M | 399.25M | 465.31M | 534.53M |
| Cost of Revenue | 68.47M | 84.44M | 98.88M | 117.78M | 136.79M |
| Gross Profit | 205.86M | 245.94M | 300.37M | 347.52M | 397.74M |
| Gross Margin | 75.0% | 74.4% | 75.2% | 74.7% | 74.4% |
| Research & Development | 48.51M | 57.34M | 73.92M | 96.18M | 90.17M |
| Selling, General & Admin | 204.65M | 231.27M | 253.14M | 291.36M | 311.02M |
| Operating Expenses | 150.66M | 288.61M | 327.05M | 387.54M | 401.19M |
| Depreciation & Amortization | 10.44M | 11.71M | 14.81M | 18.73M | 20.53M |
| EBITDA | 65.75M | (29.5M) | (8.11M) | (18.53M) | 16.25M |
| EBITDA Margin | 24.0% | -8.9% | -2.0% | -4.0% | 3.0% |
| Operating Income | 55.21M | (42.67M) | (26.68M) | (40.01M) | (3.45M) |
| Operating Margin | 20.1% | -12.9% | -6.7% | -8.6% | -0.6% |
| Interest Income | 466K | 1.99M | 3.79M | 4.43M | 4.48M |
| Interest Expense | 4.92M | 4.99M | 6.93M | 6.41M | 5.88M |
| Other Income / Expenses | (4.82M) | (3.53M) | (3.16M) | (3.66M) | (6.72M) |
| Income Before Tax | 50.39M | (46.2M) | (29.85M) | (43.67M) | (10.16M) |
| Pre-Tax Margin | 18.4% | -14.0% | -7.5% | -9.4% | -1.9% |
| Income Tax Expense | 188K | 268K | 591K | 1.02M | 1.29M |
| Net Income | 50.2M | (46.47M) | (30.44M) | (44.7M) | (11.45M) |
| Net Margin | 18.3% | -14.1% | -7.6% | -9.6% | -2.1% |
| EPS (Basic) | 1.11 | (1.02) | (0.66) | (0.95) | (0.24) |
| EPS (Diluted) | 1.09 | (1.02) | (0.66) | (0.95) | (0.24) |
| Weighted Avg Shares | 45.07M | 45.74M | 46.31M | 46.97M | 47.75M |
| Weighted Avg Shares (Diluted) | 46.04M | 45.74M | 46.31M | 46.97M | 47.75M |
AtriCure, Inc.
NASDAQ:ATRC
Intrinsic Alpha fair value
Locked
Current Price
$55.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.